U.S., May 7 -- ClinicalTrials.gov registry received information related to the study (NCT06958835) titled 'Linezolid Plus Standard of Care' on April 01.
Brief Summary: The aim of the study is to assess whether targeting virulence factors by administering linezolid in addition to standard antibiotic treatment improves outcomes in patients with Staphylococcus aureus bacteraemia.
Study Start Date: Sept., 2025
Study Type: INTERVENTIONAL
Condition:
Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia)
Intervention:
DRUG: Linezolid 600 mg
linezolid 600 mg tablets (twice a day for 5 days)
DRUG: Placebo
Placebo tablets (twice a day for 5 days)
Recruitment Status: NOT_YET_RECRUITING
Sponsor: University Hospital, Basel, Switzerla...